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Purpose: The purpose of this study was to compare the efficacy of P-selectin inhibition with standard anticoagulant and
thrombolytic therapy in a rodent model of established deep vein thrombosis (DVT).
Methods: Rats underwent temporary inferior vena cava (IVC) ligation for 2 days to create a stasis-induced thrombosis. On
day 2, the animals had the IVC ligature removed and received either recombinant P-selectin glycoprotein ligand-Ig
(rPSGL-Ig; 4 mg/kg) intravenously, low-molecular weight heparin (LMWH; 450 IU/kg) subcutaneously, tissue
plasminogen activator (tPA; 0.5 mg/kg) intravenously, combination rPSGL-Ig plus tPA, or saline vehicle. IVC segments
were harvested from rats at 4 (n 8) and 7 (n 3) days after treatment. All treatments were given as a single dose except
for daily LMWH. Evaluation included contrast venography with computer image analysis, thrombus weight/length
(mass), vein wall leukocyte counts, cytokine and tissue factor analysis with enzyme-linked immunosorbent assay, and
(ED1) monocyte immunohistochemical staining. Collagen was estimated with a quantitative assay.
Results: Contrast venography revealed that rats with both rPSGL-Ig and tPA treatment had significantly smaller thrombi
as compared with controls at day 7 (0.34  0.07 cm2 and 0.34  0.05 cm2 versus 0.68  0.13 cm2; P < .05). LMWH
and tPA groups had significantly decreased thrombus mass at harvest compared with controls on day 4 (0.06  0.009
g/cm and 0.08 0.01 g/cm versus 0.1 0.005 g/cm; P < .05), and rPSGL-Ig showed a similar trend (P .072). Vein
wall, but not thrombus, monocytes were more numerous in those rats receiving rPSGL-Ig versus controls at day 4 (30
4 cells/5 high power fields [HPFs] versus 19 2 cells/5 HPFs; P < .05) and at day 7 (32 2 cells/5 HPFs versus 20
3 cells/5 HPFs; P < .05). rPSGL-Ig treatment was associated with significantly reduced vein wall collagen at day 7 versus
controls (1.3  0.6 pg/mg versus 3.7  0.5 pg/mg; P < .05) and a trend toward lower tissue factor levels.
Conclusion: rPSGL-Ig, LMWH, and tPA showed equal DVT resolution efficacy over 7 days. However, only rPSGL-Ig
was associated with a decrease in vein wall fibrosis, suggesting that purely accelerating DVT resolution may not decrease
long-term vein scarring. (J Vasc Surg 2002;36:928-38.)
Deep venous thrombosis (DVT) is a national health
problem that affects approximately 250,000 patients year-
ly.1,2 Chronic venous insufficiency (CVI), the late sequela
of DVT, affects up to 400,000 to 500,000 patients with
skin ulceration and 6 to 7 million patients with the skin
manifestations of CVI (stasis pigmentation and stasis der-
matitis). These late manifestations are believed to be sec-
ondary to vein wall fibrosis with valvular dysfunction.
Research in various animal models suggests an integral
association between inflammation and thrombosis. Specif-
ically, a proinflammatory environment results in a local
procoagulant state and vice versa. A critical bridge between
inflammation and thrombosis are the cell adhesion mole-
cules (CAMs). CAMs, such as P-selectin, play a role in
perithrombotic inflammation and in mediating leukocyte
influx into areas of inflammation.3-7 These P-selectin-
driven interactions lead to activation of the coagulation
cascade with leukocyte tissue factor (TF) upregulation,
which further potentiates vein wall inflammatory events.5
Animal models of venous and arterial thrombosis have
shown that pretreatment with the P-selectin receptor an-
tagonist, P-selectin glycoprotein ligand-Ig (rPSGL-Ig), or
with a monoclonal antibody against P-selectin significantly
inhibits thrombus formation and accelerates thrombus res-
olution. rPSGL-Ig has been evaluated in multiple animal
species (mice, rats, cats, dogs, pigs, baboons, and cynomol-
gus macaques) and has shown only minimal effects on
platelet aggregation and coagulation parameters.6-9 Also
documented is that activated monocytes and specific che-
mokines, such as monocyte chemotactic protein-1 (MCP-
1), may accelerate thrombus resolution.10,11
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Standard therapy for DVT and pulmonary embolism
(PE) is systemic anticoagulation. Established antithrom-
botic agents, such as heparin and Coumadin, have a highly
variable dose-response relationship that can lead to severe
bleeding complications.12 Low-molecular weight heparins
(LMWHs) in recent years have become a widely used
alternative to unfractionated heparin for the treatment of
venous thromboembolic disease because of their more
predictable anticoagulant effect. Besides less bleeding com-
plications, a recent investigation in a rat model has shown
that nonanticoagulant dosing of LMWH has antiinflamma-
tory properties that lead to decreased inflammatory cell
extravasation into the vein wall.13 Active fibrinolytic agents
have efficacy in treating both DVT and PE but with signif-
icant risk of bleeding.14,15 Furthermore, the rate of throm-
bus extension/recurrence with the current anticoagulants,
including LMWH, is between 20% and 30%. Importantly,
none of the current thrombolytic agents have been shown
to decrease vein wall scarring that accompanies DVT.15-17
This investigation evaluated the efficacy of rPSGL-Ig
on enhancing thrombolysis in a rodent DVT model, com-
pared with LMWH and tissue plasminogen activator (tPA)
therapy and a combination of rPSGL-Ig with tPA. In
addition, the effect of these various agents on perithrom-
botic inflammation, TF expression, and vein wall fibrosis
was evaluated.
MATERIALS AND METHODS
Animal model
Phase I. Male Sprague-Dawley rats (n  55) approx-
imately 6 to 8 weeks old, weighing 250 to 300 g, were used
in this study. The animals underwent anesthesia with isoflu-
rane gas, 1% to 2% with nose cone, and a midline laparot-
omy was performed. Ligation of the inferior vena cava
(IVC) just below the renal veins was performed on day 0.
This included all draining side and back branches. On day
2, the animals underwent anesthesia, the main IVC ligature
was removed to potentially reestablish flow in the IVC, and
then test agents were given. Experimental groups, evalu-
ated at day 4 after treatment (n  8 per group) and at day
7 after treatment (n  3 per group) included: saline con-
trols (0.1 to 0.2 mL, intravenous bolus), LMWH (daltepa-
rin sodium, Pharmacia & Upjohn Co, Kalamazoo, Mich;
450 IU/kg, subcutaneously daily), rPSGL-Ig (Wyeth, Inc,
Andover, Mass; 4 mg/kg, intravenous bolus), tPA (Te-
necteplase, Genetech, Inc, South San Francisco, Calif; 0.5
mg/kg, intravenous bolus), and a combination of both
rPSGL-Ig (4 mg/kg, intravenous bolus) with tPA (0.5
mg/kg, intravenous bolus). The dose of rPSGL-Ig was
chosen on the basis of our previous primate work that
suggested this dose was effective for DVT prophylaxis and
treatment.7,18 The 4-day and 7-day time points were cho-
sen on the basis of previous pharmacokinetic studies that
determined rPSGL-Ig has a shorter serum half life of 4 days
in rats as compared with humans (15 days) and primates
(10 days).19 The LMWH dose was chosen from our previ-
ous rat studies that revealed a dose with both anticoagulant
and antiinflammatory properties,13 and the tPA dose was
chosen on the basis of previous studies.20 The animals were
killed at 4 and 7 days after treatment to evaluate both early
and later time points and the thrombus/IVC wall har-
vested. Thrombus evaluation included contrast venography
with computer image analysis and thrombus weight/
length (mass) calculations. Tissues were analyzed for vein
wall protein and messenger RNA (mRNA) levels, vein wall
leukocyte counts (morphometrics), vein wall collagen
quantitation, and immunohistochemical staining. In addi-
tion, coagulation tests were performed.
Phase II. A group of animals (n  34) was studied to
measure MCP-1 and TF levels in the vein wall with en-
zyme-linked immunosorbent assay (ELISA). Animal treat-
ments were divided into animals treated with saline solu-
tion for controls (n  5) and with rPSGL-Ig (n  6) and
LMWH (n  6). These animals underwent the same sur-
gical protocol and had tissue samples evaluated on days 2
and 4 after treatment.
Techniques
Thrombus mass. At death, the IVC was removed,
weighed, and measured for length. The weight then was
normalized to length (weight/length measurement). Our
previous work has shown that the major component of
weight is thrombus as opposed to the vein wall tissue itself,
and in individual or group comparisons, the vein wall
contribution to weight cancels out.4,13
Contrast venography/thrombus analysis. Venog-
raphy, anterior posterior and lateral, was performed with a
BV29 C-arm fluoroscopy unit (Phillips Medical System,
Cincinnati, Ohio) to estimate residual thrombus mass
within the IVC. Baseline venogram images of the thrombus
were obtained on day 2 at the time of IVC ligature removal.
At 4 and 7 days after treatment, venograms were taken,
captured, and digitized onto a personal computer file and
analyzed with National Institutes of Health image (version
1.62, Bethesda, Md). The vertebrae of the animals were
used to standardize the thrombus measurement as a reflec-
tion of resolution. Anterior posterior and lateral veno-
graphic images from each animal had thrombus region of
interest (ROI) measurements in cm2 evaluated and aver-
aged. The region of interest measurements were normal-
ized to baseline thrombus area and expressed as a percent-
age of initial thrombus. The evaluator was aware of the
experimental animal groupings but not appraised of the
anticipated outcomes for the different groups.
Vein wall morphometrics and immunohistochem-
isty. Paraffin-embedded sections were stained with hema-
toxylin and eosin as previously described.4,21 Five represen-
tative high power fields (HPFs; oil immersion, 1000)
were examined circumferentially around the vein wall. Cells
were identified as either neutrophils, monocyte/macro-
phages, or lymphocytes on the basis of standard histologic
criteria that included nuclear size and cytoplasmic content
as previously validated with immunohistochemical stain-
ing.21 Results from the five HPFs were totaled in a blinded
fashion.
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Immunohistochemical staining: monocyte staining.
Monocytes within the thrombus were analyzed with ED1-
positive staining as previously described.11 Slides were de-
pariffinized with two washes in xylene and graded alcohol
washes. Antigen retrieval was performed on slides with 1%
trypsin/1% CaCl2. Slides were incubated with a 1:100
dilution of mouse anti-rat ED1 (Serotec, Inc, Raleigh, NC)
for 30 minutes at room temperature. Control slides used
blocking buffer with nonspecific immunoglobulin G pri-
mary antibody (Vector Laboratories, Inc, Burlingame Cal-
if). The slides then were incubated in biotinylated second-
ary antibody diluted 1:500 in phosphate-buffered saline
solution for 30 minutes at room temperature, followed by
avidin-biotin-peroxidase complex for 30 minutes at room
temperature. Color development was performed with Vec-
tor red substrate for approximately 20 minutes, then coun-
terstained with hematoxylin quick stain.
Macrophages were quantified with digital image analy-
sis (Zeiss Axiophot, Thornwood, NY) and SPOT Image
(Spot RT Color Digital Microscope Camera, Diagnostic
Instruments, Inc, Sterling Heights, Mich) at 200 of the
entire thrombus section. The images were captured at a
resolution of 1600  1200 pixels into a TIFF format on a
Macintosh G3 computer (Apple, Inc, Cupertino, Calif).
The thrombus section area was outlined with the freehand
tool of National Institutes of Health image (version 1.61),
and the pixel area was computed. The number of macro-
phages within the clot was divided by the pixel area to allow
for comparison between the varying sized clots.
Collagen assay (sircol collagen assay). Vein wall col-
lagen content was estimated with a commercially available
kit according to manufacturer instructions (Bicolor LTD,
Belfast, North Ireland). This collagen assay measures hy-
droxyproline, with a quantitative method by which anionic
sirius red (direct red) dye binds to the side chains of basic
amino acids found in collagen.
Vein wall sandwich enzyme-linked immunosorbent
assay. Rat IVC sections were homogenized in complete
protease inhibitor cocktail (Roche Mannheim, Germany).
The suspension was sonicated on ice for 30 seconds and
centrifuged at 14,000 rpm for 10 minutes, and the super-
natant was used to run the tests in duplicate. Total vein wall
homogenate protein was determined with an assay (Pierce
BCA Assay Reagent, Rockford, Ill).
Protein antigen levels of interleukin-10 (sensitivity,
62 pg/mL), MCP-1 (sensitivity, 96 pg/mL), tumor
necrosis factor- (TNF-; sensitivity, 50 pg/mL), and
TF (sensitivity, 50 pg/mL) standardized to total protein
from homogenized vein wall samples were quantified. In
brief, commercial ELISA kits were used according to man-
ufacturer protocol (MCP-1, Endogen, Woburn, Mass;
TNF-, Endogen; interleukin-10, R&D Systems, Inc,
Minneapolis, Minn; and TF, IMUBIND, American Diag-
nostica, Greenwich, Conn). Samples were read at 450-nm
wavelength on an ELISA plate reader.
Coagulation tests and hematologic analysis. Coag-
ulation tests, at the time of tissue harvest, included acti-
vated partial thromboplastin time (aPTT), thrombin clot-
ting time (TCT), and fibrinogen (Dade Behring, Marburg,
Germany) performed per laboratory protocol.22 All tests
were run in duplicate and were reproducible within a 5%
variation.
Statistical evaluation and animal use. Statistical
analysis included the mean  the standard error of the
mean, analysis of variance, and Dunnett multiple compari-
son test. Significance was defined at a P value of .05 or less.
All rats were housed and cared for by the University of
Michigan Unit for Laboratory Animal Medicine. The Uni-
versity of Michigan is an American Association for Accred-
itation of Laboratory Animal Care-accredited facility under
the direction of a veterinarian according to the Principles of
Laboratory Animal Care (formulated by the National Soci-
ety for Medical Research) and the Guide for the Care and
Use of Laboratory Animals (National Academy of Sciences,
1996). The University of Michigan Committee on Use and
Care of Animals approved this research protocol. The au-
thors were involved in the study design, had full access to all
data in this study, and take complete responsibility for the
integrity of the data and the accuracy of the data analysis
and interpretation and for writing the manuscript and
submitting it for publication.
RESULTS
Phase I
Thrombus mass is significantly decreased with low-
molecular weight heparin and tissue plasminogen acti-
vator. Thrombus mass measurements give a reliable mea-
sure of DVT resolution. This technique assesses the entire
thrombosed vein and is performed in a standardized fash-
ion. Thrombus mass was significantly less in those animals
receiving LMWH and tPA compared with controls (0.06
0.009 g/cm and 0.08  0.01 versus 0.1  0.005 g/cm;
P .05) on day 4 only. The rPSGL-Ig treatment group had
thrombus masses that were less than those of controls, and
the trend approached significance at day 4 (0.07  0.01
g/cm versus 0.1  0.005 g/cm; P  .072). No statistical
differences in thrombus mass were noted between the
groups at day 7. This suggests an early increase in throm-
bolysis with the anticoagulant and thrombolytic agents (Fig
1).
Thrombus resolution is significantly enhanced with
recombinant P-selectin glycoprotein ligand-Ig and tis-
sue plasminogen activator. Venography allows for the
evaluation of the IVC thrombus in vivo. Contrast venogra-
phy revealed that both rPSGL-Ig and tPA had significantly
less thrombus area at day 7 as compared with controls
(0.34 0.07 cm2 and 0.34 0.05 cm2 versus 0.68 0.13
cm2; P .05). No significant difference was found between
the treated group’s thrombus area as compared with con-
trols at day 4, although the values were less in the treated
animals (Fig 2). Of interest, either based on evaluation
using thrombus mass measurements or venography, the
combination group of rPSGL-Ig  tPA was not superior.
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From review of histologic sections, it is unlikely the ob-
served differences in DVT resolution were solely from
thrombus retraction.
Recombinant P-selectin glycoprotein ligand-Ig
treatment is associated with increased vein wall mono-
cytes. From our previous studies, we have shown that
monocytes extravasate into the vein wall during DVT and
this is increased with rPSGL-Ig treatment.6,7,22 Vein wall
monocytes were more numerous in those animals receiving
rPSGL-Ig at day 4 (30  4 cells/5 HPFs versus 19  2
cells/5 HPFs; P .05) and at day 7 (32 1 cells/5 HPFs
versus 20  3 cells/5 HPFs; P  .05). The combination
group, at day 4 only, had significantly decreased neutrophil
extravasation into the vein wall (0.3  0.2 cells/5 HPFs
versus 7 0.8 cells/5 HPFs; P .01). No other significant
differences were noted in lymphocytes or total inflamma-
tory cell counts at either day 4 or day 7 between all
treatment groups (Fig 3).
Because animals treated with rPSGL-Ig had evidence of
accelerated DVT resolution, we next examined whether
thrombi monocytes were increased. Other investigators
have suggested that the monocyte is critical for DVT reso-
lution.10,11 LMWH and tPA groups had fewer positive
staining cells on day 4 only (5.2 0.9 pixels104/200
field and 4.0 1.1 pixels104/200 field) as compared
with controls (9.2  0.15 pixels 104/200 field; P 
.05). No statistically significant differences were seen in
ED1-positive staining monocyte populations between the
treatment groups at day 7. ED1-positive monocytes in
controls and in animals treated with LMWH and tPA were
uniformly distributed in the thrombus, while rPSGL-Ig
alone and in combination with tPA showed a unique dis-
tribution of monocytes at the periphery of the thrombus
near the vein wall-thrombus interface (Fig 4).
Vein wall fibrosis is significantly decreased with
recombinant P-selectin glycoprotein ligand-Ig. Peri-
thrombotic inflammation is associated with vein wall dam-
age that may manifest as later fibrosis. Vein wall collagen
was significantly decreased in the rPSGL-Ig plus tPA com-
bination group at day 4 compared with controls (2.9 0.3
Fig 1. A, Thrombus mass was significantly less in animals receiving LMWH and tPA compared with control animals
on day 4 only, and rPSGL-Ig group approached significance. B, No significant differences were noted at day 7.
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	g/mg versus 5.3  0.8 	g/mg; P  .05), and only
rPSGL-Ig treatment was associated with significantly re-
duced levels at day 7 versus controls (1.3  0.6 	g/mg
versus 3.7  0.5 	g/mg; P  .05). No anticoagulant
treatments were associated with decreased vein wall colla-
gen (Fig 5).
Cytokine vein wall expression was not altered with
treatments. Previous investigations have shown that DVT
is associated with elevations of antiinflammatory and proin-
flammatory cytokines and chemokines.22,23 However, in
this study, no significant differences in levels of MCP-1,
interleukin-10, or TNF protein expression between treat-
Fig 2. A, Examples of contrast venography show greater thrombus resolution for animal treated with rPSGL-Ig
compared with control animal. B, Contrast venography analysis revealed significant decrease in thrombus area in
animals treated with rPSGL-Ig and tPA compared with control animals at day 7.
JOURNAL OF VASCULAR SURGERY
November 2002932 Myers et al
ment groups at day 4 or day 7 were found. However,
TNF- levels were lower in the animals treated with
rPSGL-Ig at day 7 as compared with controls (191.5 
12.5 pg/mg versus 515.5  235.1 pg/mg).
Coagulation parameters were unaffected by treat-
ments. To confirm whether a constant anticoagulant ef-
fect was present after dosing at the time of tissue evaluation,
aPTT and TCT were evaluated. No adverse effects on aPTT
and TCT were found in the five groups at day 4 or day 7.
The data suggest no persistent anticoagulant effects from
anticoagulation, thrombolysis, or selectin inhibition.
Phase II
Recombinant P-selectin glycoprotein ligand-Ig up-
regulates monocyte chemotactic protein-1 and down-
regulates tissue factor during thrombosis. Because
other studies from our laboratory have shown elevated
levels of MCP-1 in the vein walls in animals treated with
rPSGL-Ig, this cytokine and TF were evaluated on days 2
and 4 in additional rats. After IVC ligature removal, treat-
ments included control, rPSGL-Ig, and LMWH. Of inter-
est, a trend towards increasing expression of MCP-1 in the
vein wall was noted at day 4 in the rPSGL-Ig group versus
controls. TF levels at the same point showed both
rPSGL-Ig and LMWH to have approximately a 50% de-
crease in vein wall protein expression as compared with
saline solution controls, especially prominent at day 2 (Fig
6).
DISCUSSION
Our data suggest that rPSGL-Ig has efficacy similar to
LMWH and tPA in accelerating DVT resolution in a rat
model of DVT without any significant effect on the coag-
ulation system. Importantly, only rPSGL-Ig was associated
with decreased vein wall fibrosis at 1 week after treatment.
Previous work from our laboratory with a primate model of
DVT has shown that P-selectin inhibition, administered
prophylactically and after DVT genesis, accelerates throm-
bus resolution, but the effects on vein wall scarring were
not investigated.6,18 Vein wall fibrosis contributes to the
stiffening of the vein and valvular dysfunction that often
occurs after DVT resolution. Human studies with serial
duplex scan imaging suggest that faster and more complete
DVT resolution is associated with a lesser incidence rate of
Fig 3. Vein wall monocytes were significantly increased in those animals receiving rPSGL-Ig at days 4 and 7.
Combination group (combo) had significantly decreased neutrophil extravasation into vein wall at day 4 only. No other
significant differences were noted in lymphocytes or total inflammatory cells at either day 4 or day 7 between all
treatment groups
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CVI.23,24 However, most DVT when diagnosed are treated
with rapid anticoagulation, and although this therapy de-
creases the recurrence of DVT (and lowers the risk of PE),
it does not necessarily decrease vein wall damage. Indeed,
in a clinical study of patients with DVT who could not
tolerate anticoagulation therapy and had an IVC filter
placed, no significant difference in CVI symptoms were
noted as compared with those on concurrent anticoagulant
therapy.25
Fibrosis is a natural end result of an inflammatory
process such as a healing wound, pulmonary injury, or
DVT. The fibrosis that results after DVT may contribute to
CVI, oftentimes debilitating young patients. No significant
antifibrotic effect was observed with either LMWH or tPA,
despite an increased rate of DVT resolution as measured
with thrombus mass and venography. The fact that LMWH
has been reported to have an antiinflammatory effect and is
associated with decreased vein wall leukocyte influx13,26
Fig 4. ED1-positive monocytes showed unique arrangement within thrombus. Microscopic examination (hematox-
ylin and eosin, 37.5) of saline solution control animals showed uniformly distributed monocytes in thrombus.
rPSGL-Ig group (black arrows) tended to have monocytes distributed at the periphery of thrombus near the vein
wall-thrombus interface at both days 4 and 7.
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suggests that other contributing factors are involved in
preventing fibrosis, when considering thrombolysis, antiin-
flammatory actions, and the vein wall response. Clinically,
this belief is supported by many patients who undergo rapid
anticoagulant treatment for a DVT but still go on to manifest
CVI disease. Further, clinical trials of tPA and other lytic
agents have failed to show improved long-term results as
compared with standard heparin,17 again suggesting that
purely speeding thrombolysis may not decrease vein wall
scarring. P-selectin inhibition may decrease vein wall fibrosis
by several mechanisms. First, rPSGL-Ig inhibits platelet-plate-
let and platelet-leukocyte interactions and thus may decrease
the activation state of the platelets with decreased release of
growth factors, such as platelet-derived growth factor.27 Sec-
ond, by inhibiting neutrophil-
2 integrin-mediated events,
such as superoxide and protease release,28 less vein wall dam-
age and subsequent fibrosis may result. In addition, rPSGL-Ig
decreases monocyte TF expression, as shown in this study and
others,5,29 and this is important because TF is both a proin-
flammatory and procoagulant factor.30,31 The combination
group of rPSGL-Ig tPA showed an increase in hydroxypro-
line levels, but notably this experimental group showed a wide
standard error for reasons yet to be determined.
Cell adhesion molecules have integral roles in modulat-
ing and localizing inflammatory reactions. P-selectin is not
only important in mediating the early step leukocyte rolling
and tethering, but in an experimental model where this
CAM is overexpressed, a procoagulant state results.3
rPSGL-Ig has direct antiinflammatory properties in addi-
tion to its anticoagulant effects in other thrombosis exper-
Fig 5. Vein wall collagen assay protein levels were significantly decreased in rPSGL-Ig  tPA combination group at
day 4 (n  8) compared with control animals, and only rPSGL-Ig treatment group was associated with significantly
reduced levels at day 7 (n  3) versus control animals.
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imental models.6,7,9 The exact mechanism has not yet been
well defined but may be due to blockade of downstream
platelet-activating factor release.32 rPSGL-Ig has been
shown to provide an antiinflammatory and survival advan-
tage in animal models of hemorrhagic shock and ischemia
reperfusion.33-35
Low-molecular weight heparin works primarily
through the inhibition of activated factor Xa, thereby
blocking further thrombus propagation and tipping the
balance in favor of natural thrombolysis. Future rodent
studies are planned to evaluate the combined effects of
rPSGL-Ig on thrombolysis with both standard heparin and
LMWH.
Tissue plasminogen activator directly converts plasmin-
ogen to plasmin that breaks down fibrin. Both of these
proteins have proven efficacious in speeding thrombus
resolution in this study, as confirmed by decreased throm-
bus mass at day 4 as compared with controls. It was
unexpected that the combination of rPSGL-Ig and tPA was
not synergistic in terms of enhancing DVT resolution.
Fig 6. A, Trend towards increasing expression of MCP-1 in vein wall as compared with control animals was noted at
day 4 in rPSGL-Ig group. B, TF levels revealed that both rPSGL-Ig and LMWH had decreased vein wall protein
expression versus control animals, especially at day 2, approaching 50% decline.
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However, tPA may alter the thrombus matrix such that the
effect of rPSGL-Ig was negated. Importantly, the animals
in the combination group revealed physiologic distur-
bances that included diarrhea, lethargy, bowel distention,
and one spontaneous death. The mechanisms that are
responsible for the nonbeneficial effect of the rPSGL-Ig 
tPA remain to be evaluated in future studies but may lie
within the optimal dose selection of the two compounds.
Thrombosis, measured with contrast venography and
thrombus mass, was not identical either at day 4 or at day 7.
This discrepancy is likely because of the difference in what
was measured. For example, venography measures only the
lumen of the vein, and thrombus mass measures both the
lumen and the vein wall. In the presence of an occlusive
thrombus, venography may be less accurate and likewise, at
later time points, thrombus mass may be influenced by
perivenous scar tissue.
P-selectin glycoprotein ligand-Ig acts to both inhibit
further thrombosis and “destabilize” the thrombus that
does develop in a manner not dissimilar to clinically avail-
able platelet glycoprotein IIb/IIIa antagonists.36 TF is a
membrane glycoprotein that, after tissue injury, activates
factor VIIa of the extrinsic pathway to accelerate the clot-
ting cascade.30,31 Our findings suggest that TF levels were
decreased in the vein walls of animals given rPSGL-Ig
approximately 50% as compared with controls. Other in-
vestigators have found that rPSGL-Ig inhibits TF mRNA
expression in rodent trauma models and that genetically
modified animals without P-selectin show decreased TF
mRNA.37 The ability of rPSGL-Ig to block P-selectin-
dependent monocyte TF expression and fibrin formation,
thus allowing for endogenous mechanisms of thrombolysis
to occur, is likely one of the mechanisms operative in this
study. Importantly, P-selectin inhibition does not signifi-
cantly alter the basic coagulation system, and thus, there is
little risk of bleeding complications.6,7,9
Monocytes play a critical role in many inflammatory
processes, including DVT resolution. From this study and
prior investigations in a primate model,6,7 rPSGL-Ig was
associated with an increased number of monocytes within
the vein wall as compared with controls. This observation
may be from the compensatory upregulation of other
CAMs, such as intracellular adhesion molecule-1, that me-
diate leukocyte transmigration. Monocytes secrete a large
number of profibrotic mediators, such as transforming
growth factor-
, basic fibroblast growth factor, and plate-
let-derived growth factor, and are documented sources of
endogenous plasminogen activators, such as tPA and uroki-
nase. Also, monocytes may have different functional phe-
notypes depending on their environment10,38,39 and can
also break down fibrin with non-plasmin mediated, but 
2
integrin-dependent, internalization.40 Although this study
did not specifically address the in vivo function of vein wall
monocytes, it hypothesized that rPSGL-Ig treatment, per-
haps with the direct P-selectin-signaling inhibition, pro-
motes a monocyte phenotype that has decreased TF expres-
sion and increased plasminogen activator expression.
MCP-1 levels, which tended to be elevated in rPSGL-
Ig-treated vein walls, correspond to an increased number of
monocytes. Endothelial cells, smooth muscle cells, and
monocytes are sources of this chemokine, a prototypic
cysteine-cysteine chemokine that is a chemoattractant and
activator of monocytes.41 Conversely, MCP-1 elevation
may just be a surrogate marker for an increased concentra-
tion of monocytes within the vein wall. Although the
thrombus levels of MCP-1 were not directly analyzed in
this study, no significant increase was seen in thrombus
monocytes. However, rPSGL-Ig treatment was associated
with a monocyte distribution that was concentrated in the
thrombus periphery, whereas LMWH, tPA, and controls
had more homogeneous distribution. This may be a result
of MCP-1 localizing monocytes at the vein wall-thrombus
interface with release of plasminogen activators to enhance
thrombolysis. Further, other investigators have found that
exogenous MCP-1 increases thrombus resolution in a rat
model of DVT.11 Interestingly, rPSGL-Ig treatment was
associated with increased neutrophils at day 7, and we have
found that inhibition of the cytokine receptor responsible
for neutrophil extravasation (CXCR2) is associated with
impaired DVT resolution (unpublished observations).
Thus, early leukocyte inhibition may not be advantageous
for thrombus resolution and may not confer an antifibrotic
effect.
Clinically, rPSGL-Ig treatment represents an exciting
experimental therapy to treat established DVT with equal
efficacy in enhancing thrombolysis as current therapies,
while also having an antifibrotic action. Further studies in
animal models are in progress to better define the natural
history of vein wall fibrosis after DVT and the biochemical
and molecular factors by which P-selectin inhibition pro-
motes such an antifibrotic effect. In addition, studies to
determine the effect of fibrosis at later time points of
approximately 28 to 30 days are planned to determine
whether the observed differences in fibrosis in this study
reflect a delay or a true inhibition.
REFERENCES
1. Coon WW. Epidemiology of venous thromboembolism. Ann Surg
1977;186:149-64.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan
NA, Jovanovic B, et al. A population-based perspective of the hospital
incidence and case-fatality rates of deep vein thrombosis and pulmonary
embolism. The Worcester DVT study. Arch Intern Med 1991;151:
933-8.
3. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD.
Pro-coagulant state resulting from high levels of soluble P-selectin in
blood. Proc Natl Acad Sci U S A 2000;97:13835-113840.
4. Henke PK, Debrunye LA, Strieter RM, Bromberg JS, Prince M, Kadell
AM, et al. Viral IL-10 gene transfer decreases inflammation and cell
adhesion molecule expression in a rat model of venous thrombosis.
J Immunol 2000;164:2131-41.
5. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, et al.
P-selectin induces the expression of tissue factor on monocytes. Proc
Natl Acad Sci U S A 1994;91:8767-71.
6. Wakefield TW, Strieter RM, Schaub R, Myers DD, Prince MR, Wrob-
leski SK, et al. Venous thrombosis prophylaxis by inflammatory inhibi-
tion without anticoagulation therapy. J Vasc Surg 2000;31:309-24.
JOURNAL OF VASCULAR SURGERY
Volume 36, Number 5 Myers et al 937
7. Myers DD Jr, Schaub R, Wrobleski SK, Londy FJ, Fex BA, Chapman
AM, et al. P-Selectin antagonism causes dose-dependent venous throm-
bosis inhibition. Thromb Haemost 2001;85:423-9.
8. Toombs CF, DeGraaf GL, Martin JP, Geng JG, Anderson DC, She-
buski RJ. Pretreatment with a blocking monoclonal antibody to P-
selectin accelerates pharmacological thrombolysis in a primate model of
arterial thrombosis. J Pharmacol Exp Ther 1995;275:941-9.
9. Kumar A, Villani MP, Patel UK, Keith JC Jr, Schaub RG. Recombinant
soluble form of PSGL-1 accelerates thrombolysis and prevents reocclu-
sion in a porcine model. Circulation 1999;99:1363-9.
10. Burnard KG, Gaffney PJ, McGuinness CL, Humphries J, Quarmby JW,
Smith A. The role of the monocyte in the generation and dissolution of
arterial and venous thrombi. Cardiovasc Surg 1998;6:119-25.
11. Humphries J, McGuinness CL, Smith A, Waltham M, Poston R,
Burnand KG. Monocyte chemotactic protein-1 (MCP-1) accelerates
the organization and resolution of venous thrombi. J Vasc Surg 1999;
30:894-900.
12. Hirsh J, Weitz JI. New antithrombotic agents. Lancet 1999;353:
1431-6.
13. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ,
Wakefield TW. Low-dose low molecular weight heparin is anti-inflam-
matory during venous thrombosis. J Vasc Surg 1998;28:848-54.
14. Elliott CG. Thrombolytic therapy. In: Hull RD, Raskab GE, Pineo G,
editors. Venous thromboembolism: an evidence-based atlas. Armuk,
NY: Futura; 1996. p. 253.
15. Becker RC, Fintel DJ, Green D, editors. Thrombolytic agents. In:
Antithrombotic therapy. 1st ed. Caddo (OK): Professional Communi-
cations, Inc; 2000. p. 41-56.
16. Kakkar VV, Lawrence D. Haemodynamic and clinical assessment after
therapy for acute deep vein thrombosis, a prospective study. Am J Surg
1985;150:54-93.
17. Goldhaber SZ, Buring JE, Libnick RJ, Hennekens CH. Pooled analysis
of randomized trials of streptokinase and heparin in phlebographically
documented acute deep vein thrombosis. Am J Med 1984;76:393-7.
18. Myers DD Jr, Wrobleski SK, Londy FJ, Fex BA, Hawley AE, Schaub
RG, et al. New and effective treatment of experimentally induced
venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb Hae-
most 2002;87:374-82.
19. Khor SP, McCarthy K, Dupont M, Murray K, Timony G. Pharmacoki-
netics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig
for phase 1 trial. J Pharmacol Exp Ther 2000;293:618-24.
20. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH,
Beriolo S, et al. Safety assessment of single-bolus administration of TNK
tissue-plasminogen activator in acute myocardial infarction: the AS-
SENT-1 trail. Am Heart J 1999;137:786-91.
21. Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK,
Burdick MD, et al. Venous thrombosis-associated inflammation and
attenuation with neutralizing antibodies to cytokines and adhesion
molecules. Arterioscler Thromb Vasc Biol 1995;15:258-68.
22. Myers DD Jr, Wrobleski SK, Henke PK, Wakefield TW. Coagulation
biology. In: Souba W, Wilmore D, editors. Surgical research, 1st ed. San
Diego: Academic Press; 2001. p. 989-1000.
23. Wakefield TW, Strieter RM, Downing LJ, Kadell AM, Wilke CA,
Burdick MD, et al. P-selectin and TNF inhibition reduce venous
thrombosis inflammation. J Surg Res 1996;64:26-31.
24. Meissner MH, Manzo RA, Bergeline RO, Markel A, Strandness DE.
Deep venous insufficiency: the relationship between lysis and subse-
quent reflux. J Vasc Surg 1993;18:596-608.
25. Proctor MC, Greenfield LJ. Recurrent thromboembolism in patients
with vena cava filters. J Vasc Surg 2001;33:510-4.
26. Nelson RM, Cecconi O, Roberts GW, Aruffo A, Linhardt RJ, Bevilac-
qua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit
acute inflammation. Blood 1993;82:3253-8.
27. Frenette PS, Wagner DD. Adhesion molecules: part II: blood vessels
and blood cells. N Engl J Med 1996;335:43-5.
28. Walzog B, Seifert R, Zakrzewicz A, Gaehtgens P, Ley K. Cross linking
of CD18 in human neutrophils induces an increase of intracellular
Ca2, exocytosis of azuroophilic granules, quantitative up-regulation
of CD18, shedding of L-selectin and actin polymerization. J Leukoc
Biol 1994;56:625-35.
29. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, et
al. Leukocyte accumulation promoting fibrin deposition is mediated in
vivo by P-selectin on adherent platelets. Nature 1992;359:848-51.
30. Mackman N. Regulation of the tissue factor gene. Thromb Haemost
1997;78:747-54.
31. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothe-
lial cell expression of tissue factor: a role for cell-cell contact and
cross-talk. Blood 1997;89:541-9.
32. Lorant DE, Topham MK, Whatley RE, McEver RP, McIntyre TM,
Prescott SM, et al. Inflammatory roles of P-selectin. J Clin Invest
1993;92:559-70.
33. Takada M, Nadeua KC, Shaw GD, Marquette KA, Tilney NL. The
cytokine-adhesion molecule cascade in ischemia/reperfusion injury of
the rat kidney: inhibition by a soluble P-selectin ligand. J Clin Invest
1997;99:2682-90.
34. Ramos-Kelly JR, Toledo-Pereyra LH, Jordan J, Rivera-Chavez F, Rohs
T, Holevar M, et al. Multiple selectin blockade with a small molecule
inhibitor downregulates liver chemokine expression and neutrophil
infiltration after hemorrhagic shock. J Trauma 2000;49:92-100.
35. Hayward R, Lefer AM. Acute mesenteric ischemia and reperfusion:
protective effects of recombinant soluble P-selectin glycoprotein li-
gand-1. Shock 1999;12:201-7.
36. Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R,
et al. Comparative real-time effects on platelet adhesion and aggrega-
tion under flowing condition of in vivo aspirin, heparin, and monoclo-
nal antibody fragment against glycoprotein IIb-IIIa. Circulation 1995;
91:1354-62.
37. Armstead VE, Minchenko AG, Scalla R, Lefer AM. Pulmonary tissue
factor mRNA expression during murine traumatic shock: effect of
P-selectin blockade. Shock 2001;15:323-6.
38. Appleton I, Tomlinson A, Colville-Nash PR, Willoughby DA. Tempo-
ral and spatial immunolocalization of cytokines in murine chronic
granulomatous tissue. Lab Invest 1993;69:405-14.
39. Ziegler-Heitbrock HWL, Stobel M, Kieper D, Fingerele G, Schlunck T,
Petersmann I, et al. Differential expression of cytokines in human
monocyte subpopulations. Blood 1992;79:503-11.
40. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J. Fibrinogen
is internalized and degraded by activated human monocytoid cells via
Mac-1(CD 11b/CD18): a nonplasmin fib rinolytic pathway. Blood
1993;82:2414-22.
41. Rollins BJ. Chemokines. Blood 1997;90:909-28.
Submitted Feb 28, 2002; accepted Jul 8, 2002.
JOURNAL OF VASCULAR SURGERY
November 2002938 Myers et al
